Laser firm focuses on limb ischaemia after femoral setback
This article was originally published in Clinica
Executive Summary
Excimer laser firm Spectranetics is pinning its hopes on FDA approval of its on critical limb ischaemia (CLI) treatment following the failure of its angioplasty trial in treating the superficial femoral artery.